Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul;16(7):689-97.
doi: 10.1038/ni.3206.

The diverse role of RIP kinases in necroptosis and inflammation

John Silke  1 , James A Rickard  1 , Motti Gerlic  2
Affiliations
Review

The diverse role of RIP kinases in necroptosis and inflammation

John Silke et al. Nat Immunol. 2015 Jul.

Erratum in

Abstract

Inflammation is a healthy response to infection or danger and should be rapid, specific and terminated once the threat has passed. Inflammatory diseases, where this regulation fails, cause considerable human suffering. Treatments have successfully targeted pro-inflammatory cytokines, such as tumor-necrosis factor (TNF), that directly induce genes encoding inflammatory products. Inflammatory signals, including TNF, may also directly induce caspase-independent cell death (necroptosis), which can also elicit inflammation. Necroptosis was originally defined as being dependent on the kinase RIPK1 but is now known to be dependent on RIPK3 and the pseudo-kinase MLKL. Therefore, RIPK1, RIPK3 and MLKL are potential therapeutic targets. RIPK1 and RIPK3 also directly regulate inflammatory signaling, which complicates interpretation of their function but might alter their therapeutic utility. This Review examines the role of cell death, particularly necroptosis, in inflammation, in the context of recent insights into the roles of the key necroptosis effector molecules RIPK1, RIPK3 and MLKL.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Elife. 2014 Dec 02;3:null - PubMed
    1. Immunity. 2011 Mar 25;34(3):340-51 - PubMed
    1. Nat Commun. 2015 Feb 18;6:6282 - PubMed
    1. PLoS Pathog. 2012;8(6):e1002723 - PubMed
    1. Science. 2014 Mar 21;343 (6177):1357-60 - PubMed

MeSH terms

LinkOut - more resources